Predictors of recurrent hospital admissions among prostate cancer survivors.

Cancer survivors often have poor outcomes compared to their peers without cancer. Mortality from prostate cancer has been steadily decreasing, and these cancer survivors have other comorbidities that progress over time. Current study explores the type of admissions and associated risk factors with recurrent hospitalizations among prostate cancer survivors. A retrospective review of medical records was performed at a single academic institution for male patients aged 40 years and older who were diagnosed with prostate cancer more than 2 years prior to the study's observation period from January 2008 to December 2010. Unpaired t test and Chi-square tests were used to compare patients' characteristics, and logistic regression models were used to assess risk factors association with recurrent admissions. In total, 245 prostate cancer survivors were stratified by single versus recurrent hospital admission. The characteristics of the study population were similar to the exception of mean Gleason score that was lower, while cardiovascular admissions and clinical comorbidities were higher in the recurrent group. In the multivariable regression analyses where sociodemographic, primary prostate cancer treatment-related sequelae and clinical comorbid conditions were simultaneously analyzed, congestive heart failure (OR 3.90, 95% CI 1.25-12.2) and history of metastasis (OR 8.10, 95% CI 1.10-60.1) were associated with recurrent hospital admissions. Prostate cancer survivors experience a greater number of recurrent admissions, and therefore, understanding the nature of these admissions and associated medical comorbidities may help us in developing screening or preventive strategies to reduce the readmissions for this group of cancer survivors.

Medical hospitalizations in prostate cancer survivors.

The objectives of the study were to explore the context and reasons for medical hospitalizations among prostate cancer survivors and to study their relationship with obesity and the type of prostate cancer treatment. A retrospective review of medical records was performed at an academic institution for male patients aged 40 years and older who were diagnosed and/or treated for prostate cancer 2 years prior to the study's observation period from January 2008 to December 2010. Unpaired t test, ANOVA, and Chi-square tests were used to compare patients' characteristics, admission types, and medical comorbidities by body mass index (BMI) and prostate cancer treatment. Mean age for the study population was 76 years (SD = 9.2). Two hundred and forty-five prostate cancer survivors were stratified into two groups: non-obese (BMI < 30 kg/m(2)) and obese (BMI ≥ 30 kg/m(2)). The study population's characteristics analyzed by BMI were similar including Gleason score, presence of metastatic disease and genitourinary-related side effects. Only 13 % of admissions were for complaints related to their genitourinary system. Neither the specific treatment that the patients had received for their prostate cancer, nor obesity was associated with the reasons for their medical admission. Survivorship after having a diagnosis of prostate cancer is often lengthy, and these men are at risk of being hospitalized, as they get older. From this inquiry, it has become clear that neither body mass index nor prior therapy is associated with specific admission characteristics, and only a minority of such admissions was directly related to prostate cancer or the genitourinary tract.